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A B S T R A C T
Purpose
Symptoms and complications of metastatic colorectal cancer (mCRC) differ by metastatic sites. There is a
paucity of prospective survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC).
We characterized outcomes of patients with pcCRC enrolled onto two prospective randomized trials of
chemotherapy and contrasted that with other manifestations of mCRC (non-pcCRC).
Methods
A total of 2,095 patients enrolled onto two prospective randomized trials were evaluated for overall
survival (OS) and progression-free survival (PFS). A Cox proportional hazard model was used to
assess the adjusted associations.
Results
The characteristics of the pcCRC group (n  364) were similar to those of the non-pcCRC
patients in median age (63 v 61 years, P  .23), sex (57% males v 61%, P  .23), and
performance status (Eastern Cooperative Oncology Group performance status 0 or 1 94% v
96%, P  .06), but differed in frequency of liver (63% v 82%, P  .001) and lung metastases
(27% v 34%, P  .01). Median OS (12.7 v 17.6 months, hazard ratio [HR]  1.3; 95% CI, 1.2
to 1.5; P  .001) and PFS (5.8 v 7.2 months, HR  1.2; 95% CI, 1.1 to 1.3; P  .001) were
shorter for pcCRC versus non-pcCRC. The unfavorable prognostic influence of pcCRC remained after
adjusting for age, PS, liver metastases, and other factors (OS: HR  1.3, P  .001; PFS: HR  1.1,
P  .02). Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and
fluorouracil as a first-line treatment among pcCRC (HR for OS  0.62, P  .005) and non-pcCRC
patients (HR  0.66, P  .001).
Conclusion
pcCRC is associated with a significantly shorter OS and PFS as compared with other manifestations of
mCRC. Future trials for mCRC should consider stratifying on the basis of pcCRC status.
J Clin Oncol 30:263-267. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Symptoms and complications associated with met-
astatic colorectal cancer (mCRC) differ by meta-
static sites. In clinical practice, the differences among
several distinct types of mCRC have been apparent
for decades. Best survival is achieved among those
for whom a combination of contemporary systemic
chemotherapy1-3 and a surgical resection is possible.
Respective 5-year survival rates for selected popula-
tions are nearly 60%, 40%, and 20% to 51% among
those with resectable hepatic,4-6 pulmonary,7,8 and
peritoneal metastases.9-11
Peritoneal carcinomatosis from CRC (pc-
CRC) has been historically associated with a
very poor prognosis. Studies including systemic
chemotherapy and symptom-directed surgery
without cytoreduction demonstrated a median
survival ranging from 5.2 to 7 months in the era
of fluorouracil (FU) -only treatment.12-15 A
subset of patients presenting with bowel ob-
struction owing to peritoneal carcinomatosis
have an even worse prognosis, with a median
overall survival (OS) for those actively treated
of approximately 3 to 4 months and a 17%
1-year survival rate.16,17
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The combination of systemic chemotherapy after aggressive cy-
toreduction surgery with concurrent intraperitoneal chemotherapy
has demonstrated a remarkable improvement in survival for highly
selected patients with pcCRC (hazard ratio [HR]  0.55) in a prospec-
tive randomized trial9,18 and in several retrospective surgical stud-
ies.10,11,19 Nevertheless, there is a paucity of prospectively collected
outcome data for patients with peritoneal carcinomatosis treated with
systemic chemotherapy. Therefore, we characterized the clinical
course of patients with pcCRC enrolled in two cooperative group
prospective randomized trials of systemic chemotherapy and con-
trasted that with mCRC with a different metastatic pattern (non-
pcCRC). We hypothesized that pcCRC is associated with worse
prognosis. If pcCRC is indeed a prognostic factor for mCRC, stratifi-
cation of future systemic chemotherapy trials and exploration of other
modalities for pcCRC should be considered.
METHODS
Prospective controlled randomized protocols of the North Cancer Central
Treatment Group trials for patients with metastatic colorectal cancer were
analyzed. Three trials collected information on site of metastatic disease. Data
regarding the pcCRC status for an older trial (894652) were not available and
therefore have not been included in this study. Two other trials met inclusion
criteria (N9741 and N9841) and have available data (Table 1). N9741 exam-
ined multiple first-line chemotherapy regimens among patients with meta-
static colorectal cancer.1 This trial was modified during enrollment, resulting
in the majority of patients treated with irinotecan, leucovorin, and fluorouracil
(IFL); irinotecan and oxaliplatin (IROX); and infusional fluorouracil, leuco-
vorin, and oxaliplatin (FOLFOX) regimens (n  1,691). N9841 (n  491)
enrolled patients for second-line systemic chemotherapy after prior FU treat-
ment and randomly assigned between irinotecan and FOLFOX.3 Reported
results are based on 2,101 cases without consent cancellations (n  30), major
protocol violations (n  27), or ineligibility (n  24). Analyses of pcCRC
status are based on 2,095 cases as a result of missing data on metastatic sites in
six patients (two cases for N9741 and four cases for N9841). Local institutional
review boards approved the parent studies and the Mayo Clinic institutional
review board approved the present analysis.
Most patients with pcCRC have radiologically nonmeasurable perito-
neal disease, and progression may occur outside of peritoneum, making
progression-free-survival (PFS) difficult to measure reliability. Therefore, we
chose OS as the main clinical outcome, with limited reporting of PFS.
The stratified log-rank test was used to compare OS and PFS between
pcCRC and non-pcCRC patients with combined data from two trials. The
distributions of survival outcomes were estimated by Kaplan-Meier curves.
The impact of systemic chemotherapy was analyzed separately for first-
(N9741) and second-line treatment (N9841). A Cox proportional hazards
model was used to assess the adjusted associations stratified by study. Analyses
were done using SAS version 9.2 (SAS Institute, Cary, NC) and R version 2.11
(http://www.r-project.org).
RESULTS
Of a total of 2,101 patients were included; the majority participated
in the N9741 trial of first-line chemotherapy for mCRC (n  1,646),
andtheremainingparticipated intheN9841trialof second-linechem-
otherapy (n  455). Although age statistically differed between the
trials, the difference was clinically trivial (Table 2). There was no age
difference when stratified by presence or absence of pcCRC (Table 3).
pcCRC was more common among those enrolled in the second-line
trial (22.6% v 15.9%, P  .001; Table 2), with a total of 17.4%. Patients
with pcCRC as the sole presentation of mCRC were uncommon in
this patient population (n  44, 2.1%; Table 2). Despite having less
hepatic and pulmonary metastases, the patients with pcCRC were
more likely to harbor more metastatic disease sites (Table 3). Prior
adjuvant chemotherapy (N9741) and prior systemic therapy (N9841)
was collected differently between the two studies, had a high rate of
missing data, and could not be factored into the analysis.
Patients with pcCRC had higher risk of death owing to all
causes than patients without pcCRC (median OS 12.7 v 17.6
months, HR  1.32, 95% CI, 1.15 to 1.50; P  .001; Fig 1, Table 4).
Among patients treated with first-line FOLFOX, median OS was 15.7
months versus 20.9 months for pcCRC versus non-pcCRC patients,
respectively (P  .003; Fig 2). After 7 years median follow-up on living
patients, 2,009 (98.5%) of 2,095 patients with known pcCRC status
have died. Both 5-year (6% v 4.1%) and 8-year (3.2% v 1.1%) survival
rates were higher among those without pcCRC than with pcCRC.
Data on tumor grade were not available. Involvement of regional
lymph nodes did not predict OS (HR  1.012, P  .820) or PFS
(HR  0.970, P  .580) in univariate Cox model stratified by study.
Table 1. Trial and Chemotherapy Description
Trial Label Trial Name Arm Label Chemotherapy
N9741 A Randomized Phase III Trial of Combinations
of Oxaliplatin, 5-Fluorouracil, and Irinotecan
as Initial Treatment of Patients With
Advanced Adenocarcinoma of the Colon
and Rectum
Arm A: IFL (Saltz regimen) Irinotecan 100 mg/m2 as a 90-minute infusion  CF 20 mg/m2
as a 15-minute infusion or IV push and FU 400 mg/m2 IV
bolus weekly  4, every 6 weeks
Arm F: FOLFOX OXAL 85 mg/m2 IV infusion in 500 mL of D5W over 120
minutes on day 1 and CF 200 mg/m2 IV infusion over 120
minutes and FU 400 mg/m2 IV bolus then 600 mg/m2 IV
infusion in 500 mL of D5W over 22 hours on days 1 and 2,
every 2 weeks
Arm G: IROX OXAL 85 mg/m2 IV infusion in 500 mL of D5W over 120
minutes on day 1 and irinotecan 200 mg/m2 IV over 30
minutes on day 1 every 3 weeks
N9841 A Randomized Phase III Equivalence Trial of
Irinotecan Versus Oxaliplatin 5-Fluorouracil/
Leucovorin in Patients With Advanced
Colorectal Carcinoma Previously Treated
with 5-FU
Arm A: IRI Irinotecan 350 mg/m2 as a 90-minute infusion, day 1, every 3
weeks
Arm B: FOLFOX OXAL 85 mg/m2 as a 2-hour infusion, day 1,  CF 200 mg/m2
(2-hour infusion) followed by FU 400 mg/m2 followed by FU
600 mg/m2 (22-hour infusion), days 1 and 2, every 2 weeks
Abbreviations: CF, leucovorin; D5W, 5% dextrose in water; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; FU, fluorouracil; IFL, irinotecan, leucovorin,
and fluorouracil; IROX, irinotecan and oxaliplatin; IV, intravenous; OXAL, oxaliplatin.
Franko et al
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Within N9741, there is no statistically significant evidence of
interaction effect (P  .799) between pcCRC status and treatment
groups on OS. Adjusting for status of pcCRC, IFL (HR  1.53, P  .001)
and IROX (HR  1.34, P  .001) were associated with poorer OS than
FOLFOX. Adjusting for treatments, patients with pcCRC had worse
OS (HR  1.42, P  .001) than patients with non-pcCRC.
Similar results were obtained when analyzing second-line treat-
ment in N9841: There was no significant interaction (P  .115) be-
tween pcCRC status and treatment groups on OS. Adjusting for
treatments, patients with pcCRC had worse OS than patients with
non-pcCRC (HR  1.37, P  .006). However, there is no statistically
significant difference in OS between IRI and FOLFOX (HR  1.10,
P  .321) after adjusting for pcCRC status.
To estimate efficacy of various chemotherapy regimens on OS,
separate analyzes were performed by trial and pcCRC status (Fig 2 and
Appendix Fig A1, online only). OS was similar for patients with pc-
CRC and non-pcCRC treated with second-line FOLFOX (Appendix
Fig A1, online only). Patients with pcCRC fared significantly worse in
all other settings.
PFS was not a primary objective of this analysis. Nevertheless, pa-
tientswithpcCRCfaredworseinbothunivariateanalysis(medianPFS5.8
v 7.2 months, P  .002) and multivariate analysis (HR  1.16, P  .021).
DISCUSSION
Theprognostic impactofspecificmetastaticsiteshasbeenrecognizedand
included in staging of patients with melanoma and ovarian cancer. Al-
though less well studied in mCRC, available evidence suggests an espe-
cially poor prognosis in patients with peritoneal carcinomatosis12-15
treated by systemic chemotherapy. Reported median survival among se-
lected patients with good performance status treated with cytoreductive
surgeryplusintraperitonealandsystemicchemotherapyis22.3monthsin
a prospective randomized trial9,18 and 33 to 61 months in the most recent
retrospective comparative studies.10,11
Although a few prospective studies on peritoneal carcinomatosis are
available,15,18,20 this report is by far largest and is, to our knowledge, the
Table 2. Demographic Characteristics Stratified by Study: N9741 (first-line








PNo. % No. % No. %
Age, years .029
Mean 60.1 61.4 60.4
SD 11.5 11.7 11.6
pcCRC 262 15.9 102 22.6 364 17.4  .001
pcCRC (solitary site) 28 1.7 16 3.5 44 2.1 .015
Liver metastases 1,347 81.9 295 65.4 1,642 78.4  .001
Pulmonary
metastases 513 31.2 176 39.0 689 32.9 .002
Male sex 998 60.6 267 58.7 1,265 60.2 .451
ECOG performance
status .286
0-1 1,569 95.3 439 96.5 2,008 95.6
2 77 4.7 16 3.5 93 4.4
No. of disease sites .446
Missing data 2 4 6
1 601 36.6 175 38.8 776 37.0
2 572 34.8 160 35.5 732 34.9
3 471 28.6 116 25.5 587 27.9
Abbreviations: ECOG, Eastern Cooperative Oncology Group; pcCRC, perito-
neal carcinomatosis colorectal cancer; SD, standard deviation.








PNo. % No. % No. %
Age, years .225
Mean 60.3 60.6 60.4
SD 11.3 12.9 11.6
Male sex 1,052 60.8 209 57.4 1,261 60.2 .234
ECOG performance
status .055
0-1 1,661 96.0 341 93.7 2,002 95.6
2 70 4.0 23 6.3 93 4.4
Disease status .069
Measurable 1,443 83.4 289 79.4 1,732 82.7
Evaluable 288 16.6 75 20.6 363 17.3
Liver metastases 1,414 81.7 228 62.6 1,642 78.4  .001
Pulmonary
metastases 590 34.1 99 27.2 689 32.9 .011
No. of disease
sites  .001
1 734 42.4 42 11.5 776 37.0
2 615 35.5 117 32.1 732 34.9
3 382 22.1 205 56.3 587 27.9
Treatment group .6188
FU 52 3 7 1.9 59 2.8
IFL or IRI 585 33.8 120 33.0 705 33.7
IROX 304 17.6 70 19.2 374 17.9
FOLFOX 790 45.6 167 45.9 957 45.7
Prior adjuvant
therapy
Missing info 349 102 451
Given 187 13.5 53 20.2 240 14.6
Not given 1,195 86.5 209 79.8 1,404 85.4
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FOLFOX, infu-
sional fluorouracil, leucovorin, and oxaliplatin; FU, fluorouracil; IFL, irinotecan,
leucovorin, and fluorouracil; IRI, irinotecan; IROX, irinotecan and oxaliplatin;
pcCRC, peritoneal carcinomatosis colorectal cancer; SD, standard deviation.






















1 2 3 4 5 6 7 8
Fig 1. Overall survival by peritoneal carcinomatosis colorectal cancer (pc-
CRC) status.
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only study that analyzes survival differences on the basis of pcCRC status.
The negative prognostic impact of pcCRC on OS observed in this study
hasbeenconsistentlyshowninunivariate(bothunadjustedandadjusted)
and multivariate analysis. The magnitude of this impact was consistent
(HR  1.3) and is clinically relevant.
We observed no differential impact of systemic chemotherapy on
the basis of presence or absence of pcCRC. To our knowledge, the only
observation of this phenomenon in mCRC comes from Folprecht et al,20
who observed the absence of benefit from infusional FU as opposed to
bolus FU among patients with pcCRC. Second, they noted less benefit
from an FU/irinotecan combination among those with pcCRC as com-
pared with those with other forms of mCRC for OS.20 The present study
suggests superiority of FOLFOX versus IFL and IROX in the first-line
settingandnodifferencebetweenirinotecanandFOLFOXinthesecond-
linesettingafterinitialFUtreatment.Therefore,thepresenceorabsenceof
pcCRC should not affect the choice of systemic chemotherapy regimen.
We realize several apparent limitations of the present study, includ-
ing the retrospective nature of the analysis and some missing data. More-
over, carcinomatosis burden is known to substantially influence
survival,18,19,21 but cannot be estimated in this study population. Also,
selective consideration of mCRC for randomized trials may affect the
number of patients with pcCRC involved in such trials. Indeed, preva-
lence of isolated pcCRC has been reported at 10% to 15%,13,14 but was
found in only 2.1% cases in this study population.
The clinical manifestation of peritoneal carcinomatosis is unusually
variable, and caution should be exercised when applying these results in
clinical practice. More than 90% of the patients in these two studies had
excellent performance status, and inclusion criteria required expected
survival of more than 3 months. These criteria are certainly not met
among patients with pcCRC presenting with malignant bowel obstruc-
tion or ascites, for whom expected median survival remains less than 4
months.16,17Statusofregionallymphnodesdidnotpredictsurvivalinthis
study. Among studies of cytoreduction with systemic and regional chem-
otherapy, some have found nodal involvement predictive of OS,21 but
others have not.10,22 Although tumor grade is recognized as an important
survival predictor in retrospective studies on cytoreduction,10,21 we had
no available data to examine this factor.
Documented long-term survival ( 5 years) of patients with
unresectable mCRC has been approximately 1.1%23 in the FU-only
era and has increased with newer chemotherapeutic agents.1-3 In the
present study, the 5-year OS was 6% for those without pcCRC and
4.1% for those with pcCRC. On the other hand, retrospective surgical
series document nearly 60% actuarial survival among those with liver
resection5,6 and 20% to 51% among those treated with cytoreductive
surgery and intraperitoneal and systemic chemotherapy for pcCRC.9-11
Of note, these studies were limited to patients amenable to surgical con-
sideration. It remains unclear how these considerations relate to the pop-
ulation in the current study, mainly because of different selection bias
associated with randomized trials on systemic chemotherapy versus cy-
toreduction studies. Consequently, reported outcomes among patients





pcCRC (present v absent)  .0001 1.316 1.152 to 1.504
Age (per year increase) .0072 1.005 1.001 to 1.010
PS (2 v 0 & 1)  .0001 1.796 1.453 to 2.220
Disease status (evaluable v measurable) .4269 0.953 0.847 to 1.073
Liver metastases (present v absent)  .0001 1.284 1.133 to 1.455
Other metastases (present v absent) .0009 1.263 1.100 to 1.449
Grouped current sites of disease
No. of sites, 0-1 — Ref —
No. of sites, 2 .1339 1.107 0.969 to 1.263
No. of sites, 3 .1568 1.141 0.950 to 1.371
Abbreviations: pcCRC, peritoneal carcinomatosis colorectal cancer; PS, per-
formance status.
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Fig 2. Survival of N9741 (first-line chemotherapy for metastatic colorectal
cancer) by regimen used and peritoneal carcinomatosis colorectal cancer
(pcCRC) status. Survival of patients with pcCRC was inferior in all chemother-
apy arms. (A) infusional fluorouracil, leucovorin, and oxaliplatin; (B) irinotecan,
leucovorin, and fluorouracil; (C) irinotecan and oxaliplatin.
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with carcinomatosis vary far and wide. The median survival was less than
4 months among those presenting with obstruction and treated with
symptom-directed surgery and systemic chemotherapy,16,17 whereas the
majority of cytoreduction studies report median survival of more than 19
monthsaftercytoreduction,10,21 andthehighestreportedmediansurvival
is 63 months.10
In summary, peritoneal carcinomatosis among patients with
mCRC is associated with a 30% reduction in OS. Choice of sys-
temic chemotherapy should be independent of presence or absence
of peritoneal carcinomatosis. The FOLFOX regimen is superior to
IFL and IROX irrespective of carcinomatosis status. Stratification
of future prospective randomized trials based on carcinomatosis
status should be considered. Continued research on bimodality
treatment combining surgery and alternative chemotherapy deliv-
ery routes may be warranted. Molecular and genetic profiling of
colorectal cancers may establish a gene signature that is predictive
of a propensity for pcCRC and lead to selection of alternative
adjuvant or advanced disease management strategies.
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